Callio Therapeutics

I will be speaking at BioVerse EP20 on "The Trends of Asia-to-Europe Pharmaceutical Licensing Deals"! Join me on April 9 for this insightful event.

Callio Therapeutics’ Chief Business Officer Angele Maki is attending Bio-Europe Spring (17-19 March 2025).    Meet Angèle to learn more about Callio Therapeutics’ multi-payload ADC platform and programs focused on maximizing therapeutic benefit for cancer patients. If you are attending #BioEuropeSpring, reach out via partnering ONE® to schedule a meeting. 

A new-ish biotech emerged on Monday with $187 million in the ever-popular field of antibody-drug conjugates. Some of the Hummingbird Bioscience team is migrating over to Singapore and Seattle biotech Callio Therapeutics to carry forward a mutli-payload ADC pipeline. They share some of the same investors and leadership, and the spinout's name is a play on the calliope variety of hummingbird. CEO Piers Ingram said the field has “struggled” to find good payloads. “The Topo1 inhibitors have proven to be a very, very good class of payload, but there are not many others still,” the CEO said. “The best strategy would be if you could really deliver targeted combination therapies to address these resistance mechanisms to the payloads that we do have.” To realize that potential in ADCs, it “seemed to be quite challenging to find a way to really make it work within Hummingbird,” so the investors and board decided to create a separate company focused on the ADC platform, Ingram said. More from my Endpoints News interview with Callio and Hummingbird CEO Ingram: #hummingbirdbiosciences #calliotherapeutics #adc #antibodydrugconjugate #biotechvc #biotechfunding #biotechlaunch

We are thrilled to announce the launch of Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload #AntibodyDrugConjugates to improve the cancer treatment landscape. Led by CEO Piers Ingram, CSO Jerome Boyd-Kirkup, CMO Naomi Hunder and CBO Angele Maki, we are on a mission to improve outcomes for people living with cancer around the world. The US$187M Series A financing that supported today’s launch was led by Frazier Life Sciences, with an investor syndicate that also includes JEITO Capital, Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI Pte Ltd. Read the full announcement: https://lnkd.in/gVBXyRxF #CallioTx #Financing #Biotech